Loading
Defined the molecular subtypes of small-cell lung cancer and led early trials of DLL3-targeted therapy.
Charles Rudin led the consensus that split small-cell lung cancer into ASCL1, NEUROD1, POU2F3 and inflamed subtypes, giving the disease its first biology-based classification. He was a lead investigator of the rovalpituzumab tesirine and tarlatamab DLL3 programmes and of KEYNOTE-604. His laboratory studies SCLC plasticity and lineage transformation of EGFR-mutant lung cancer.
| Title | Journal | Year |
|---|---|---|
| Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data | Nature Reviews Cancer | 2019 |
| Small-cell lung cancer | Nature Reviews Disease Primers | 2021 |
It is the reality check on the subtype model and it has a direct consequence for treatment: the DLL3-directed medicines are aimed at the neuroendocrine-high subtypes, and the POU2F3 and double-negative tumours will not express the target.
It gives the sequencing report a prognostic reading that does not depend on a repeat biopsy: an EGFR-mutant cancer that also carries RB1 and TP53 alterations will stop responding sooner and should be watched for a change of histology.
The organising framework for every small-cell lung cancer trial designed since. It is also why the slow progress in the disease is now attributed to treating four diseases as one rather than to the biology being intractable.
Shares SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization, Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, DLL3, Tarlatamab.
Shares Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, DLL3, Tarlatamab, Limited-stage small-cell lung cancer.
Shares DLL3, Tarlatamab, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares DLL3, Tarlatamab, Limited-stage small-cell lung cancer, Extensive-stage small-cell lung cancer.
Shares DeLLphi-304, Tarlatamab, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares DLL3, Tarlatamab, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Tarlatamab, Limited-stage small-cell lung cancer, Small-cell lung cancer.
Shares Tarlatamab, Extensive-stage small-cell lung cancer, Small-cell lung cancer.